Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 22 | 2025 | 1103 | 4.510 |
Why?
|
| Cardiomyopathies | 6 | 2023 | 507 | 2.010 |
Why?
|
| Acute-On-Chronic Liver Failure | 4 | 2025 | 78 | 1.650 |
Why?
|
| Biliary Atresia | 4 | 2024 | 206 | 1.630 |
Why?
|
| Liver Cirrhosis | 7 | 2024 | 899 | 1.330 |
Why?
|
| Liver Failure, Acute | 4 | 2024 | 94 | 1.200 |
Why?
|
| Bile Acids and Salts | 5 | 2023 | 258 | 1.190 |
Why?
|
| Myocardium | 3 | 2021 | 907 | 1.150 |
Why?
|
| End Stage Liver Disease | 5 | 2024 | 192 | 1.010 |
Why?
|
| Multiple Organ Failure | 3 | 2022 | 144 | 0.850 |
Why?
|
| Airway Extubation | 1 | 2024 | 70 | 0.830 |
Why?
|
| Liver | 4 | 2023 | 1845 | 0.760 |
Why?
|
| Renal Replacement Therapy | 3 | 2024 | 156 | 0.680 |
Why?
|
| Respiration, Artificial | 1 | 2023 | 503 | 0.660 |
Why?
|
| Perioperative Care | 1 | 2021 | 212 | 0.610 |
Why?
|
| Myocardial Contraction | 2 | 2018 | 240 | 0.610 |
Why?
|
| Tracheostomy | 1 | 2021 | 202 | 0.600 |
Why?
|
| Cholic Acids | 1 | 2018 | 16 | 0.590 |
Why?
|
| Extracorporeal Circulation | 1 | 2018 | 55 | 0.570 |
Why?
|
| Critical Care | 2 | 2021 | 699 | 0.570 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2018 | 314 | 0.550 |
Why?
|
| Plasma Exchange | 1 | 2018 | 89 | 0.540 |
Why?
|
| Hemodynamics | 1 | 2021 | 819 | 0.540 |
Why?
|
| Cardiotonic Agents | 1 | 2018 | 142 | 0.530 |
Why?
|
| Cholic Acid | 3 | 2014 | 20 | 0.530 |
Why?
|
| Infant | 15 | 2024 | 13258 | 0.510 |
Why?
|
| Child | 23 | 2024 | 25889 | 0.450 |
Why?
|
| Retrospective Studies | 16 | 2024 | 17580 | 0.440 |
Why?
|
| Postoperative Complications | 3 | 2024 | 3170 | 0.420 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2014 | 88 | 0.410 |
Why?
|
| Pyridines | 2 | 2014 | 249 | 0.400 |
Why?
|
| Hospital Costs | 2 | 2024 | 187 | 0.400 |
Why?
|
| Cholestasis | 2 | 2014 | 157 | 0.390 |
Why?
|
| Thrombolytic Therapy | 1 | 2014 | 214 | 0.380 |
Why?
|
| Fibrinolytic Agents | 1 | 2014 | 209 | 0.380 |
Why?
|
| Child, Preschool | 14 | 2024 | 14905 | 0.370 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 190 | 0.360 |
Why?
|
| Waiting Lists | 2 | 2021 | 236 | 0.350 |
Why?
|
| Heart Atria | 1 | 2013 | 331 | 0.340 |
Why?
|
| Male | 25 | 2024 | 65658 | 0.340 |
Why?
|
| Bile Duct Diseases | 1 | 2010 | 17 | 0.330 |
Why?
|
| Anticoagulants | 4 | 2022 | 629 | 0.310 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2010 | 157 | 0.290 |
Why?
|
| Diet, Atherogenic | 1 | 2008 | 16 | 0.290 |
Why?
|
| Myocytes, Cardiac | 1 | 2013 | 644 | 0.290 |
Why?
|
| Thrombosis | 3 | 2022 | 544 | 0.290 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2011 | 375 | 0.280 |
Why?
|
| Humans | 30 | 2025 | 133529 | 0.280 |
Why?
|
| Citric Acid | 2 | 2018 | 39 | 0.280 |
Why?
|
| Hepatitis | 1 | 2008 | 58 | 0.280 |
Why?
|
| Prognosis | 4 | 2024 | 5052 | 0.270 |
Why?
|
| Blood Group Incompatibility | 2 | 2018 | 27 | 0.270 |
Why?
|
| Adolescent | 10 | 2024 | 20606 | 0.270 |
Why?
|
| ABO Blood-Group System | 2 | 2018 | 66 | 0.260 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2008 | 145 | 0.260 |
Why?
|
| Risk Factors | 6 | 2024 | 10970 | 0.260 |
Why?
|
| Mice, Knockout | 5 | 2023 | 3978 | 0.260 |
Why?
|
| Heart | 2 | 2011 | 692 | 0.250 |
Why?
|
| Liver Diseases | 2 | 2022 | 389 | 0.250 |
Why?
|
| Mice, Inbred C57BL | 6 | 2023 | 4826 | 0.250 |
Why?
|
| Atrial Fibrillation | 1 | 2013 | 699 | 0.240 |
Why?
|
| Length of Stay | 3 | 2024 | 1398 | 0.240 |
Why?
|
| Female | 18 | 2024 | 71561 | 0.230 |
Why?
|
| Heart Failure | 1 | 2018 | 2429 | 0.230 |
Why?
|
| Treatment Outcome | 8 | 2022 | 13101 | 0.220 |
Why?
|
| Critical Illness | 4 | 2021 | 630 | 0.220 |
Why?
|
| Ferritins | 2 | 2021 | 109 | 0.200 |
Why?
|
| Adenovirus Infections, Human | 1 | 2023 | 57 | 0.190 |
Why?
|
| Necrosis | 1 | 2022 | 211 | 0.180 |
Why?
|
| Gastroenterology | 1 | 2024 | 210 | 0.180 |
Why?
|
| Hemodiafiltration | 1 | 2021 | 18 | 0.180 |
Why?
|
| Intensive Care Units | 2 | 2018 | 539 | 0.180 |
Why?
|
| Fatty Acids | 2 | 2016 | 367 | 0.180 |
Why?
|
| Survival Rate | 2 | 2024 | 2203 | 0.170 |
Why?
|
| ADAMTS13 Protein | 1 | 2021 | 67 | 0.170 |
Why?
|
| Bacterial Infections | 1 | 2023 | 327 | 0.170 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2021 | 149 | 0.170 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 174 | 0.160 |
Why?
|
| Animals | 9 | 2023 | 36121 | 0.160 |
Why?
|
| Gastroenteritis | 1 | 2023 | 366 | 0.160 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 4766 | 0.160 |
Why?
|
| Bacteremia | 1 | 2023 | 430 | 0.150 |
Why?
|
| von Willebrand Factor | 1 | 2021 | 205 | 0.150 |
Why?
|
| Ventricular Function, Left | 2 | 2014 | 542 | 0.150 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 5453 | 0.150 |
Why?
|
| Serum Albumin, Human | 1 | 2018 | 8 | 0.150 |
Why?
|
| Cause of Death | 2 | 2018 | 504 | 0.150 |
Why?
|
| Hemofiltration | 1 | 2018 | 11 | 0.150 |
Why?
|
| Sepsis | 1 | 2023 | 522 | 0.150 |
Why?
|
| Cytoprotection | 1 | 2018 | 38 | 0.150 |
Why?
|
| Signal Transduction | 4 | 2018 | 4918 | 0.150 |
Why?
|
| Biliary Tract Diseases | 1 | 2018 | 37 | 0.150 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2018 | 67 | 0.140 |
Why?
|
| Preoperative Period | 1 | 2018 | 93 | 0.140 |
Why?
|
| Liver Failure | 1 | 2018 | 91 | 0.140 |
Why?
|
| Exercise Tolerance | 1 | 2018 | 87 | 0.140 |
Why?
|
| Survival Analysis | 1 | 2021 | 1584 | 0.140 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1305 | 0.140 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 283 | 0.130 |
Why?
|
| Infant, Newborn | 4 | 2024 | 8633 | 0.120 |
Why?
|
| Echocardiography | 2 | 2019 | 1120 | 0.120 |
Why?
|
| Mice | 6 | 2023 | 18910 | 0.110 |
Why?
|
| Time Factors | 3 | 2017 | 6545 | 0.110 |
Why?
|
| Tissue Donors | 1 | 2018 | 507 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 677 | 0.110 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2013 | 19 | 0.110 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2014 | 91 | 0.100 |
Why?
|
| Drug Resistance | 1 | 2014 | 263 | 0.100 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2014 | 198 | 0.100 |
Why?
|
| Catheterization | 1 | 2014 | 238 | 0.100 |
Why?
|
| Cells, Cultured | 1 | 2018 | 3141 | 0.100 |
Why?
|
| Cardiovirus Infections | 1 | 2011 | 7 | 0.090 |
Why?
|
| Radiography | 1 | 2014 | 822 | 0.090 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2011 | 51 | 0.090 |
Why?
|
| Portal Vein | 2 | 2022 | 86 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2014 | 463 | 0.090 |
Why?
|
| Dicarbethoxydihydrocollidine | 1 | 2010 | 3 | 0.080 |
Why?
|
| Ventricular Remodeling | 1 | 2011 | 173 | 0.080 |
Why?
|
| Glycogen | 1 | 2010 | 54 | 0.080 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2010 | 59 | 0.080 |
Why?
|
| Myocarditis | 1 | 2011 | 132 | 0.080 |
Why?
|
| Recurrence | 1 | 2014 | 1470 | 0.080 |
Why?
|
| Respiratory Function Tests | 1 | 2010 | 216 | 0.080 |
Why?
|
| Amino Acids | 2 | 2023 | 684 | 0.080 |
Why?
|
| Gene Expression | 2 | 2013 | 1608 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2019 | 5205 | 0.080 |
Why?
|
| Oxygen Consumption | 1 | 2010 | 309 | 0.080 |
Why?
|
| Fatigue | 1 | 2010 | 198 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2018 | 3450 | 0.080 |
Why?
|
| Chemokine CXCL2 | 1 | 2008 | 5 | 0.070 |
Why?
|
| Fibrosis | 1 | 2010 | 426 | 0.070 |
Why?
|
| Cholesterol, Dietary | 1 | 2008 | 48 | 0.070 |
Why?
|
| Chemokine CCL5 | 1 | 2008 | 52 | 0.070 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2008 | 59 | 0.070 |
Why?
|
| Chemokine CCL2 | 1 | 2008 | 121 | 0.070 |
Why?
|
| Heart Ventricles | 1 | 2011 | 783 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2011 | 981 | 0.060 |
Why?
|
| Dietary Fats | 1 | 2008 | 297 | 0.060 |
Why?
|
| Fatty Liver | 1 | 2008 | 212 | 0.060 |
Why?
|
| Organ Dysfunction Scores | 1 | 2025 | 52 | 0.060 |
Why?
|
| Asia | 1 | 2025 | 126 | 0.060 |
Why?
|
| Brain Edema | 1 | 2024 | 71 | 0.050 |
Why?
|
| Biomarkers | 1 | 2014 | 3417 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 3097 | 0.050 |
Why?
|
| India | 1 | 2024 | 239 | 0.050 |
Why?
|
| Receptors, Purinergic | 1 | 2023 | 16 | 0.050 |
Why?
|
| Receptors, Purinergic P2Y2 | 1 | 2023 | 17 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1468 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 1136 | 0.050 |
Why?
|
| Nucleotides | 1 | 2023 | 95 | 0.050 |
Why?
|
| Texas | 1 | 2011 | 3668 | 0.050 |
Why?
|
| Adenoviruses, Human | 1 | 2023 | 98 | 0.050 |
Why?
|
| Cytokines | 2 | 2023 | 1381 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 1467 | 0.050 |
Why?
|
| GTP-Binding Proteins | 1 | 2023 | 187 | 0.050 |
Why?
|
| Hepatic Artery | 1 | 2022 | 46 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2023 | 315 | 0.050 |
Why?
|
| Catheters | 1 | 2022 | 89 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2011 | 3725 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2008 | 2880 | 0.040 |
Why?
|
| Consensus | 1 | 2025 | 713 | 0.040 |
Why?
|
| Arginine | 1 | 2023 | 348 | 0.040 |
Why?
|
| Thrombectomy | 1 | 2021 | 110 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2024 | 409 | 0.040 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 121 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2021 | 103 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2021 | 108 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2023 | 806 | 0.040 |
Why?
|
| Phenotype | 1 | 2010 | 4581 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2021 | 6586 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2023 | 604 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2024 | 788 | 0.040 |
Why?
|
| Graft Survival | 1 | 2022 | 480 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2018 | 243 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1431 | 0.030 |
Why?
|
| Linear Models | 1 | 2018 | 720 | 0.030 |
Why?
|
| United States | 2 | 2024 | 11761 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1179 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2018 | 566 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2021 | 892 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 676 | 0.030 |
Why?
|
| Mice, Inbred DBA | 1 | 2013 | 53 | 0.030 |
Why?
|
| Mice, 129 Strain | 1 | 2013 | 100 | 0.030 |
Why?
|
| Mutant Proteins | 1 | 2013 | 120 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2013 | 393 | 0.020 |
Why?
|
| Calcium | 1 | 2017 | 1103 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2017 | 1097 | 0.020 |
Why?
|
| Disease Progression | 1 | 2018 | 2249 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2013 | 246 | 0.020 |
Why?
|
| Encephalomyocarditis virus | 1 | 2011 | 8 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 787 | 0.020 |
Why?
|
| Adult | 2 | 2024 | 31787 | 0.020 |
Why?
|
| Young Adult | 1 | 2024 | 9980 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 844 | 0.020 |
Why?
|
| Viral Load | 1 | 2011 | 407 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2013 | 828 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 548 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 1136 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 2956 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1321 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1749 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1938 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 2520 | 0.020 |
Why?
|